PH12022550509A1 - Anti-cd73 antibodies - Google Patents

Anti-cd73 antibodies

Info

Publication number
PH12022550509A1
PH12022550509A1 PH1/2022/550509A PH12022550509A PH12022550509A1 PH 12022550509 A1 PH12022550509 A1 PH 12022550509A1 PH 12022550509 A PH12022550509 A PH 12022550509A PH 12022550509 A1 PH12022550509 A1 PH 12022550509A1
Authority
PH
Philippines
Prior art keywords
antibodies
cancer
activity
methods
relates
Prior art date
Application number
PH1/2022/550509A
Other languages
English (en)
Inventor
Lise Camilla Frã–Hlich
Torben Gjetting
Michael Monrad Grandal
Randi Westh Hansen
Janus Schou Jakobsen
Johan Lantto
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PH12022550509A1 publication Critical patent/PH12022550509A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH1/2022/550509A 2019-09-06 2020-09-04 Anti-cd73 antibodies PH12022550509A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962896908P 2019-09-06 2019-09-06
PCT/EP2020/074804 WO2021044005A1 (en) 2019-09-06 2020-09-04 Anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
PH12022550509A1 true PH12022550509A1 (en) 2023-03-20

Family

ID=72517218

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550509A PH12022550509A1 (en) 2019-09-06 2020-09-04 Anti-cd73 antibodies

Country Status (18)

Country Link
US (2) US11634500B2 (https=)
EP (1) EP4025605A1 (https=)
JP (1) JP7662617B2 (https=)
KR (1) KR20220057558A (https=)
CN (1) CN115023439B (https=)
AU (1) AU2020342778A1 (https=)
BR (1) BR112022003956A2 (https=)
CA (1) CA3153213A1 (https=)
CL (1) CL2024002093A1 (https=)
CO (1) CO2022002622A2 (https=)
IL (1) IL291068A (https=)
MX (1) MX2022002682A (https=)
MY (1) MY207784A (https=)
PE (1) PE20220708A1 (https=)
PH (1) PH12022550509A1 (https=)
TW (1) TWI859319B (https=)
UA (1) UA130408C2 (https=)
WO (1) WO2021044005A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
JP2023532234A (ja) * 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US338841A (en) 1886-03-30 herden
US256055A (en) 1882-04-04 Compound engine
US323997A (en) 1885-08-11 Machine-gun
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
WO2006113181A2 (en) 2005-04-08 2006-10-26 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
WO2006125140A2 (en) 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
JP2017514458A (ja) * 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
CA2988119A1 (en) 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
ES2924402T3 (es) 2015-10-02 2022-10-06 Symphogen As Anticuerpos anti-PD-1 y composiciones
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CN114805575B (zh) 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
US20200232974A1 (en) 2016-03-30 2020-07-23 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
JP7066690B2 (ja) * 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
PH12019500668B1 (en) * 2016-10-13 2023-12-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof

Also Published As

Publication number Publication date
MX2022002682A (es) 2022-04-07
AU2020342778A1 (en) 2022-03-31
WO2021044005A1 (en) 2021-03-11
CN115023439A (zh) 2022-09-06
US11634500B2 (en) 2023-04-25
CO2022002622A2 (es) 2022-04-08
JP7662617B2 (ja) 2025-04-15
KR20220057558A (ko) 2022-05-09
US20210070876A1 (en) 2021-03-11
IL291068A (en) 2022-05-01
BR112022003956A2 (pt) 2022-05-24
UA130408C2 (uk) 2026-02-11
JP2022547081A (ja) 2022-11-10
US20230227573A1 (en) 2023-07-20
TWI859319B (zh) 2024-10-21
MY207784A (en) 2025-03-18
CN115023439B (zh) 2026-04-03
CL2024002093A1 (es) 2024-12-27
EP4025605A1 (en) 2022-07-13
PE20220708A1 (es) 2022-05-04
NZ785824A (en) 2025-10-31
CA3153213A1 (en) 2021-03-11
TW202122423A (zh) 2021-06-16

Similar Documents

Publication Publication Date Title
PH12022550509A1 (en) Anti-cd73 antibodies
MY203971A (en) Anti-lag-3 antibodies and compositions
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MY190324A (en) Anti-pd-1 antibodies and compositions
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12022551150A1 (en) Biparatopic cd73 antibodies
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MY205760A (en) Humanized antibodies against c-kit
PH12021553000A1 (en) Multispecific proteins
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MX384346B (es) Bloqueo de cd73.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MY209381A (en) Anti-axl antibodies and compositions
WO2020186111A3 (en) Vista-binding antibodies and uses thereof
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations